Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127062762 | 12706276 | 2 | F | 20160824 | 20160901 | 20160906 | EXP | JP-MLMSERVICE-20160811-0388597-1 | JP-INVENTIA-000133 | INVENTIA HEALTHCARE | NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY. 2016 | 64.00 | YR | F | Y | 77.20000 | KG | 20160906 | MD | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127062762 | 12706276 | 1 | PS | METFORMIN | METFORMIN HYDROCHLORIDE | 1 | U | 201991 | 2250 | MG | |||||||||
| 127062762 | 12706276 | 2 | SS | CANDESARTAN | CANDESARTAN | 1 | U | 0 | 8 | MG | |||||||||
| 127062762 | 12706276 | 3 | SS | OLMESARTAN/OLMESARTAN MEDOXOMIL | OLMESARTAN | 1 | U | 0 | 20 | MG | |||||||||
| 127062762 | 12706276 | 4 | SS | GLIMEPIRIDE. | GLIMEPIRIDE | 1 | U | 0 | 1 | MG | |||||||||
| 127062762 | 12706276 | 5 | C | VOGLIBOSE | VOGLIBOSE | 1 | 0 | .9 | MG | ||||||||||
| 127062762 | 12706276 | 6 | C | EXENATIDE | EXENATIDE | 1 | 0 | 20 | UG | ||||||||||
| 127062762 | 12706276 | 7 | C | AMLODIPINE | AMLODIPINE BESYLATE | 1 | 0 | 5 | MG | ||||||||||
| 127062762 | 12706276 | 8 | C | ROSUVASTATIN/ROSUVASTATIN CALCIUM | 2 | 0 | 2.5 | MG | |||||||||||
| 127062762 | 12706276 | 9 | C | TOCOPHEROL | TOCOPHEROL | 1 | 0 | 600 | MG | ||||||||||
| 127062762 | 12706276 | 10 | C | POLAPREZINC | POLAPREZINC | 1 | 0 | 150 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127062762 | 12706276 | 1 | Type 2 diabetes mellitus |
| 127062762 | 12706276 | 2 | Product used for unknown indication |
| 127062762 | 12706276 | 3 | Product used for unknown indication |
| 127062762 | 12706276 | 4 | Type 2 diabetes mellitus |
| 127062762 | 12706276 | 5 | Type 2 diabetes mellitus |
| 127062762 | 12706276 | 6 | Type 2 diabetes mellitus |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127062762 | 12706276 | OT |
| 127062762 | 12706276 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127062762 | 12706276 | Dehydration | |
| 127062762 | 12706276 | Escherichia urinary tract infection | |
| 127062762 | 12706276 | Hypoglycaemia | |
| 127062762 | 12706276 | Lactic acidosis | |
| 127062762 | 12706276 | Peripheral circulatory failure | |
| 127062762 | 12706276 | Renal impairment | |
| 127062762 | 12706276 | Urinary tract infection |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |